New FDA Rules Impose Objectivity on Drug Approvals

The Food and Drug Administration (FDA) announced last week that it intends to implement a tougher  approach when considering potential conflicts of interest for its advisory committee members and for recommending eligibility for meeting participation. Doctors who receive more than $50,000 from a company or a competitor whose product is being discussed would no longer be allowed to serve on the committees.

The new rules are important, as these doctors, powerful advisers who receive payments from drug companies, have enormous influence over ultimately what drugs are approved, and this has shown to be a potentially dangerous situation for the public, while making drug companies millions of dollars.

Leave a Reply

Your email address will not be published. Required fields are marked *